Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials

OBJECTIVE: To investigate serum protein expression in participants with psoriatic arthritis (PsA) and changes after guselkumab treatment. METHODS: Participants with PsA were treated with guselkumab or placebo in the DISCOVER-1 and DISCOVER-2 studies. Serum levels of acute phase reactants C reactive...

Descripción completa

Detalles Bibliográficos
Autores principales: Sweet, Kristen, Song, Qingxuan, Loza, Matthew J, McInnes, Iain B, Ma, Keying, Leander, Karen, Lakshminarayanan, Vani, Franks, Carol, Cooper, Philip, Siebert, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137258/
https://www.ncbi.nlm.nih.gov/pubmed/34011674
http://dx.doi.org/10.1136/rmdopen-2021-001679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137258/
https://www.ncbi.nlm.nih.gov/pubmed/34011674
http://dx.doi.org/10.1136/rmdopen-2021-001679

Ejemplares similares